Table 3 Additional benefit claims based on types of sponsor
From: Phase IV non-inferiority trials and additional claims of benefit
| Â | Â | Additional benefit (row percentage) | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Not mentioned | Convenient method of administration | Better safety profile | Better compliance | Less costly | Convenient method of administration and better safety profile | Convenient method of administration, better safety profile, better resistance profile |
Type of initiators | Non-pharmaceutical industry (n = 12) | 7 (59) | 0 | 4 (33) | 0 | 0 | 0 | 1 (8) |
Pharmaceutical industry (n = 25) | 11 (44) | 1 (4) | 8 (32) | 1 (4) | 1 (4) | 3(12) | 0 | |
Not clear (n = 4) | 1(25) | 0 | 0 | 2 (50) | 0 | 1 (25) | 0 | |
Conclusion of the trial | Non-inferiority (n = 30) | 15 (50) | 1 (3) | 8 (27) | 3 (10) | 0 | 2 (7) | 1 (3) |
Superiority (n = 2) | 0 | 0 | 2(100) | 0 | 0 | 0 | 0 | |
Inferiority (n = 6) | 2 (33) | 0 | 1(17) | 0 | 1(17) | 2 (33) | 0 | |
|  | Other (n = 3) | 2 (67) | 0 | 1 (33) | 0 | 0 | 0 | 0 |